Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Most relevant news about GILEAD SCIENCES
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19BioCentury - Allogene names Schmidt CFO
AQ
06/19Payers, drugmakers face off over CAR T Medicare coverage
AQ
06/15ViiV's two-drug HIV regimen meets in Phase III for HIV
AQ
06/14GILEAD SCIENCES : Ex-dividend day for
FA
06/13GILEAD SCIENCES' : Chief Scientific Officer John McHutchison Appointed Officer o..
AQ
06/12GSK says vaccine business president to leave by year-end
RE
06/11GILEAD SCIENCES : rsquo; Chief Scientific Officer John McHutchison Appointed Off..
BU
06/11GILEAD SCIENCES : Nomination
CO
06/08ATARA BIOTHERAPEUTICS, INC. (NASDAQ : ATRA) Files An 8-K Departure of Directors ..
AQ
06/07DRC approves investigational Ebola treatments
AQ
06/06GILEAD SCIENCES : Kite Announces Initial Results from a Phase 1 Study of T cell ..
AQ
06/04GILEAD SCIENCES : Announces Leadership Changes in Corporate Development and Stra..
BU
06/04GILEAD SCIENCES : Kite Announces Initial Results From a Phase 1 Study of T Cell ..
BU
More most relevant news
All news about GILEAD SCIENCES
06/22Celgenes CAR T Cell Therapy Could Be Long-Term Growth Driver
AQ
06/21GILEAD SCIENCES : Patent Issued for Method for Treating a Pulmonary Hypertension..
AQ
06/21GILEAD SCIENCES' : Chief Scientific Officer John McHutchison Appointed Officer o..
AQ
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19BioCentury - Allogene names Schmidt CFO
AQ
06/19Payers, drugmakers face off over CAR T Medicare coverage
AQ
06/15Glaxo Pops But Analysts Say It`s Unlikely To Swipe Gilead Share In HIV
AQ
06/15ViiV's two-drug HIV regimen meets in Phase III for HIV
AQ
06/14GILEAD SCIENCES : Announces Leadership Changes in Corporate Development and Stra..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement -- Update
DJ
More sector news : Bio Therapeutic Drugs
Official Publications
06/11Nomination 
05/10Report 
05/08Report 
05/03Report 
05/011st quarter results 
05/01Dividends 
More official Publications
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/22ARBUTUS BIOPHARMA : The Next Big Breakout Biotech? 
06/21JOHNSON & JOHNSON : Strong Company, But Won't Fit In Most Portfolios 
06/211 High-Yield Blue Chip Set To Soar And 1 You Should Ignore 
06/203 THINGS IN BIOTECH, JUNE 19 : Geron Just Can't Win, Verastem Breaks Out 
06/19Does Gilead's Have A HBV Blockbuster Drug In The Works? 
Latest Tweets
06/23TheScreener - GILEAD SCIENCES INCO. sees an upgrade to Slightly Positive due .. 
06/22Column: Horror is an everyday banality in Gilead. It shouldn't be the same fo..
3
06/22$ABUS $GILD  
06/22Want the latest upgrades & downgrades for $OXLC $GILD $BIIB $KEYN $HGSI? .. 
06/22A "David vs Goliaths" battle over the future of the Mount Gilead Estate is ex.. 
More tweets
Qtime:360
Financials ($)
Sales 2018 20 794 M
EBIT 2018 10 734 M
Net income 2018 6 433 M
Debt 2018 13 028 M
Yield 2018 3,20%
P/E ratio 2018 14,36
P/E ratio 2019 13,08
EV / Sales 2018 5,07x
EV / Sales 2019 5,15x
Capitalization 92 410 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 85,8 $
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES-0.80%92 410
VERTEX PHARMACEUTICALS3.10%40 566
REGENERON PHARMACEUTICALS-11.70%35 172
GENMAB-3.97%9 557
SAREPTA THERAPEUTICS INC152.21%9 196
NEUROCRINE BIOSCIENCES, INC.31.19%9 151